LATAM H1N1 Vaccination Market Size & Outlook, 2026-2034


LATAM H1N1 Vaccination Market Insights

  • Reed Intelligence analysis indicates that the LATAM H1N1 Vaccination Market size, which was USD 426.5 Million in 2025, is projected to attain USD 804.11 Million by 2034.
  • The market is expected to register a CAGR of 7.34% over the period 2026–2034.
  • In 2025, Inactivated H1N1 Vaccines emerged as the dominant Vaccine Type based on market size.
  • Recombinant H1N1 Vaccines is projected to register the fastest growth, positioning it as the most attractive Vaccine Type segment over the forecast horizon.

Other Key Findings


  • In 2025, LATAM accounted for 5.44% of the global H1N1 Vaccination Market size.
  • By 2034, United States is projected to lead the global market in terms of market size.
  • Brazil is projected to emerge as the fastest-growing market in LATAM, reaching USD 369.57 Million by 2034.

Report Summary

Report Scope Details
Base Year for Study 2025
Study Period 2022-2034
Historical Period 2022-2024
Forecast Period 2026-2034
Market Size In 2025 USD 426.5 Million
Market Size In 2034 USD 804.11 Million
Largest segment Inactivated H1N1 Vaccines
Units Revenue in USD Million
CAGR 7.34% (2026-2034)
Segmnetation Covered
LATAM
  1. Brazil
  2. Mexico
  3. Argentina
  4. Colombia
  5. Chile
Vaccine Type
  1. Inactivated H1N1 Vaccines
  2. Live Attenuated H1N1 Vaccines
  3. Cell-Based H1N1 Vaccines
  4. Recombinant H1N1 Vaccines
Age Group
  1. Pediatric Vaccination
  2. Adult Vaccination
  3. Geriatric Vaccination
Distribution Channel
  1. Hospital and Public Health Procurement
  2. Retail Pharmacy Distribution
  3. Online Pharmacy Channels
Route of Administration
  1. Injectable Vaccines
  2. Intranasal Vaccines
End User
  1. Public Immunization Programs
  2. Private Healthcare Providers
  3. Community Vaccination Centers
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Related Reports